Trial Profile
A phase 1/2a study of subcutaneous administration of P28R
Status:
Planning
Phase of Trial:
Phase I/II
Latest Information Update: 09 Dec 2018
Price :
$35
*
At a glance
- Drugs Peptides (Primary)
- Indications Head and neck cancer
- Focus Adverse reactions; Therapeutic Use
- 09 Dec 2018 New trial record
- 28 Nov 2018 According to a CanImguide Therapeutics media release, the company planning to initiate this study in 2019.